A double-blind, placebo-controlled, parallel group study of oral trovafloxacin on bowel microflora in healthy male volunteers

American Journal of Surgery

Volumn 176, Issue 6 A, 1998, Pages 27S-31S

  Van Nispen, Claartje H M ^a   Hoepelman, Andy I M ^a   Rozenberg Arska, Marja ^a   Verhoef, Jan ^a   Purkins, Lynn ^b   Willavize, Susan A ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TROVAFLOXACIN;

ADULT; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL OVERGROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG PENETRATION; DRUG POTENCY; ENTEROBACTERIACEAE; FECES MICROFLORA; HUMAN; HUMAN EXPERIMENT; INTESTINE FLORA; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032466997     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(98)00217-7     Document Type: Article

References (15)

1. Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukaemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med. 1987; 106:7-12.
2. Rozenberg-Arsaka M, Dekker AW, Verhoef J. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukaemic drug remission induction treatment: the effect on faecal flora. J Infect Dis. 1985;152:104-107.
3. Enzensberger R, Shah PM, Knothe H. Impact of oral ciprofloxacin on faecal flora of healthy volunteers. Infection. 1985;13/6:273-275.
4. Neu HC, Chin N-X. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother. 1994;38:2615-2622.
5. Child J, Andrews J, Boswell F, et al. The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother. 1995;35:869-876.
6. Sefton AM, Maskell JP, Rafay AM, et al. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against gram-positive bacteria. J Antimicrob Chemother. 1997;39(suppl B):57-62.
7. Klugman K, Wasas A. In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae. J Antimicrob Chemother. 1995;36:873-874.
8. Thomson KS, Chartrand SA, Sanders CC, Block SL. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother. 1997;41:478-480.
9. Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother. 1997;39(suppl B):1-14.
10. Teng R, Liston TE, Harris SC. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother. 1996;37:955-963.
11. Vincent J, Venitz J, Teng R, et al. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. J Antimicrob Chemother. 1997;39(suppl B):75-80.
12. Melnik G, Schwesinger WH, Dogolo LC, et al. Concentrations of trovafloxacin in colonic tissue and peritoneal fluid after intravenous infusion of the prodrug alatrofloxacin in patients undergoing colorectal surgery. Am J Surg. 1998;176(Suppl 6A):14S-17S.
13. Barry AL, Brown SD, Fuchs PC. In-vitro selection of quinolone-resistant staphylococcal mutants by a single exposure to ciprofloxacin or trovafloxacin (CP-99,219). J Antimicrob Chemother. 1996;38:324-327.
14. Gootz TD, Zaniewski R, Haskell S, et al. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother. 1996;40:2691-2697.
15. Hoepelman IM, Rozenberg-Arska M, Verhoef J. Comparative study in ceftriaxone monotherapy versus a combination regime of cefuroxime plus gentamicin for treatment of serious bacterial infections: the efficacy, safety and effect on faecal flora. Chemotherapy. 1988;34:21-29.